Evaluating the Durability & Biomarkers of Tolerance & Exploring Delivery Systems to Drive Antigen-Specific Immune Tolerance Approaches to Achieve Clinical Efficacy
The 10th Antigen-Specific Immune Tolerance Summit returns at a defining moment for the field, bringing together presenters from Diamyd Medical, COUR Pharmaceuticals, Integrated NanoTherapeutics, BreezeBio, and more to share the latest preclinical and clinical advances shaping antigen-specific immune tolerance. From pivotal Phase III data and clinical findings from treated patients to next-generation delivery technologies and novel mRNA platforms, these presentations highlight a field entering a critical phase of clinical validation. Alongside these developments, companies including Bonsai Biotherapeutics and Parvus Therapeutics continue to advance innovative tolerance-inducing approaches, demonstrating the growing momentum across the broader ecosystem
As programs mature, the focus is shifting from demonstrating biological activity to proving durable clinical efficacy, defining meaningful biomarkers of tolerance, and generating the evidence needed to secure regulatory approval and attract investment.
Designed to address these challenges head-on, this year's meeting will explore how the community can translate scientific promise into clinical success. As the only industry-led meeting dedicated exclusively to antigen-specific immune tolerance, the summit brings together researchers, clinicians, biopharma leaders, investors, and key opinion leaders driving progress across autoimmune and allergy.
Don't miss the 10th anniversary summit where the future of immune tolerance will be debated, challenged, and defined.
New for 2027: World Immune Tolerance Week
For the very first time, the 10th Antigen-Specific Immune Tolerance Summit is becoming part of World Immune Tolerance Week alongside the 9th Treg-Directed Therapies Summit and the 2nd Immune Resetting: B-Cell Mediated & Beyond Summit to bring together the full autoimmune and immunology disease community. While each summit retains its own scientific focus, expert speaker faculty, and community, attendees will gain access to all three meetings, enabling cross-disciplinary learning, richer networking, and collaboration across antigen-specific therapies, Treg approaches, B-cell modulation, and broader immune resetting strategies.
Attending Companies Include